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10,054 in 2005 to 8,751 in 2009 (p0.001). IC proce-
dures also fell from 123,643 in 2005 to 106,202 in
2009 (p0.001). In 2009, the presence of an AMC in a
HRR was linked to 46.3% fewer CAS procedures (IRR
0.537, 95% CI: 0.464-0.622) compared to HRR without
AMC. Higher CEA rates were also linked to fewer CAS
(IRR0.755, 95% CI: 0.687-0.829), while higher rates of
IC and IR procedures were associated with more CAS
(IRR1.028, 95% CI 1.021-1.036; IRR1.083, 95% CI
1.067-1.099).
Conclusions: Total carotid revascularization volume is
falling in CA. Increased use of CAS in a HRR is associated
with fewer CEA, the absence of an AMC, and increased
rates of IC and IR procedures.
Predictors for CAS usage in a California HRR: 2009
HRR Variable
Incidence
Rate
Ratio
95%
Confidence
Interval P value
Average rate
per 10,000
inhabitants
CEA rate 0.755 0.687-0.829 0.001 2.59
IC rate 1.028 1.021-1.036 0.001 31.61
IR rate 1.083 1.067-1.099 0.001 8.21
Presence of an AMC 0.537 0.464-0.622 0.001 N/A
Trends in CEA, CAS, and IC in California: 2005-2009
Year 2005 2006 2007 2008 2009
Carotid Artery Stenting
(CAS) 1,351 1,826 1,297 1,276 1,324
Carotid
Endarterectomy
(CEA) 8,703 8,225 8,151 8,070 7,427
Total Carotid
Revascularization
Procedures 10,054 10,051 9,448 9,346 8,751
Interventional
Cardiology
Procedures (IC) 123,643 120,317 112,192 110,250 106,202
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Objectives: To evaluate the impact of carotid plaque
type and best medical treatment (BMT) on recurrent ca-
rotid stenosis and future cardiovascular events(CVE) fol-
lowing carotid endarterectomy (CEA).
Methods: A retrospective evaluation of long-term col-
lected data was performed. A total of 559 patients with
no-patch CEAwere included in the study (645 operations).
The patients were divided into two groups, Group A: 305
patients (1990- 1999) receiving only ASA and Group B:
254 patients (2000-2009) receiving current BMT, includ-
ing statins. Patients were evaluated with color duplex at 1
and then every 6 months for the first 5 years and annually
thereafter. Mean duration of follow-up was 84 months
(range: 12-228). 11 patients (2%) were lost to follow-up.
Restenosis, CVE (stroke, myocardial infarction) and deaths
were recorded and analyzed with regard to the conven-
tional risk factors, use of statins and the ultrasonographic
characteristics of the plaques. Statistical analysis was per-
formed using Kaplan-Meier and Cox regression analysis.
Results: Freedom from restenosis 50% at 5, 10 and
15 years of follow-up was 93%, 83% and 69% respectively.
Patients with echolucent plaques (types I and II) had a
significantly higher restenosis rate compared to those with
echogenic plaques (types III and IV) at 5 (P0.05), 10 and
15 years (P0.001). Restenosis was also associated with
coronary artery disease (P0.001), diabetes mellitus
(P0.05) and no-statin use (Group A vs Group B,
P0.05). CVEs rate at 5, 10 and 15 years was 17%, 27%
and 38% respectively. Patients with echolucent plaques had
a higher incidence of CVE at 10 and 15 years (P0.001)).
Cardiovascular events were also associated with coronary
artery disease (P0.05), hypertension (P0.05) and no-
statin use (Group A vs Group B, P0.05).
Conclusions: Echolucent carotid plaques, coronary
artery disease and no-statin use are strong predictors of
restenosis and future CVE following CEA.
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Objectives: The aim of this study was to investigate the
accuracy of CT angiography (CTA), MR angiography
(MRA), and digital subtraction angiography (DSA) in
grading of carotid stenosis compared with actual measure-
ment of luminal area reduction in an in vitro model.
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